EBC-46

One Year and Beyond: What Long-Term Blushwood Extract Users Are Reporting

After a year or more of daily blushwood extract use, a cohort of verified buyers report sustained reductions in inflammation, improved energy, and unexpected clinical observations their doctors found difficult to explain.

Marcus Webb

16 Mar 2026 — 4 min read

Why Duration Changes the Significance of a Report

Scepticism about consumer supplement reports is often reasonable. Placebo responses peak in the first weeks of use and then tend to fade. Regression to the mean explains a substantial portion of self-reported improvement in the short term. But these explanations become progressively less credible as duration extends. When a verified buyer, using a product continuously for a year or more, continues to report consistent and specific improvements — and when those improvements match the known pharmacological profile of the compound — the statistical bar for dismissal rises considerably.^[1]

The accumulating cohort of long-term blushwood berry extract users now includes verified buyers who have been taking the product for well over a year. Their reports, collected through independent review platforms, share a striking pattern: persistence, specificity, and in several cases, corroboration from third parties including medical professionals. They represent the kind of signal that, in the history of pharmacology, has sometimes preceded major discoveries.

Mike Giapi: Running at 54, Inflammation Almost Gone

Mike Giapi, a verified buyer aged 54, has been using blushwood extract for more than a year. His report describes what is among the most medically concrete long-term accounts available: "All inflammation almost 90% gone." He runs six miles two to three times per week — a level of sustained aerobic activity that would be difficult or impossible for someone carrying the chronic inflammation he describes experiencing before starting the extract.^[1]

The specificity here is notable. Inflammation is not a vague wellness concept — it has measurable correlates in blood chemistry (C-reactive protein, interleukin-6, TNF-alpha) and functional consequences (joint mobility, exercise tolerance, recovery time). A 90% subjective reduction maintained over more than a year, with a level of physical activity that objectively supports the claim, places this report in a different category from a generalised feeling of improved wellbeing.^[2]

What mechanism might account for this? PKC signalling plays a documented role in inflammatory cytokine modulation. Research on PKC-delta and PKC-epsilon isoforms — the same isoforms activated by tigilanol tiglate — shows involvement in NF-κB pathway regulation, the master switch for inflammatory gene expression. Chronic anti-inflammatory activity consistent with prolonged PKC modulation is biologically plausible, though not yet clinically studied in this context.^[3]

Anna Zahn: Positive Scans During Stage 4 Treatment

Anna Zahn is a verified buyer who began taking blushwood extract in July 2023, following a diagnosis of stage 4 breast cancer that had spread to her lungs and bones. Her long-term report describes "very positive scan results" — language that, in the context of metastatic disease in the lungs and bones, carries clinical weight.^[1]

It is impossible to draw causal conclusions from this report. Stage 4 breast cancer patients receiving oncology treatment may experience partial responses for a variety of reasons, and Anna's account does not describe her conventional treatment status. What is significant is the persistence of the report and its clinical specificity: scan results are objective, not subjective. A verified buyer using a supplement for nearly three years and continuing to describe positive oncological outcomes is a signal that the research community has an obligation to examine.^[4]

Karen: Post-Sepsis, Blood Clots, and Eyes That Cleared

Among the most medically remarkable long-term reports is Karen's, submitted directly by email. Karen describes a post-sepsis condition following heavy antibiotic treatment, during which the whites of her eyes had yellowed — a clinical sign of jaundice, typically indicating hepatic or haematological stress. After beginning blushwood extract, her eyes cleared. Her doctor reviewed her blood work and attributed the resolution of blood clots to the blushwood extract, and looked it up himself.^[1]

That last detail — a physician reviewing and acknowledging the compound — elevates this report beyond patient self-report. The clearing of scleral jaundice, the resolution of post-sepsis blood clots, and physician attribution are collectively a remarkable cluster of observations. The biological pathway connecting PKC modulation to haematological and hepatic recovery mechanisms is not implausible: PKC signalling is involved in platelet activation, coagulation cascades, and hepatocyte function. But this is precisely the kind of specific, multi-system report that demands prospective clinical study.^[3]^[2]

Kim Sandquist: Optimal Immune Function, Four Months In

Kim Sandquist, a verified buyer four months into supplementation, reports: "I feel stronger and healthier... my immune system is optimal." While four months falls short of the one-year threshold, Kim's report is included here because it describes a trajectory — consistent, progressive improvement — that mirrors the longer-term accounts. The subjective sense of immune optimisation is consistent with research on PKC's role in T-cell activation and innate immune response.^[1]^[3]

The Pattern These Reports Reveal

Across Mike Giapi's sustained inflammation reduction, Anna Zahn's scan results, Karen's post-sepsis recovery, and Kim Sandquist's immune experience, a pattern emerges that is consistent with a compound acting systemically on inflammatory and immune pathways. None of these individuals knows each other. None describes their experiences in mechanistic language. Yet the pattern they describe — reduced inflammation, improved immune function, surprising clinical observations — maps onto the known biology of PKC signalling with a specificity that is difficult to attribute to placebo.^[2]^[3]

The history of pharmacology offers a clear precedent for the significance of such patterns. Aspirin's anti-inflammatory and cardioprotective effects were observed anecdotally in patients chewing willow bark for centuries before salicylic acid was isolated in 1828 and the mechanism understood in the 1970s. Artemisinin's antimalarial activity was embedded in Chinese traditional medicine for two millennia before Tu Youyou won the Nobel Prize for its characterisation. Metformin was derived from French lilac used in medieval medicine for diabetes-like symptoms.^[4]

These long-term blushwood reports are not proof of mechanism. But they are exactly the kind of signal that has historically preceded pharmacological discovery. The research community has not yet run the studies needed to evaluate them. That is the gap that deserves to close.